Archive for the 'Rosetta Genomics' Category

Rosetta Genomics news feed.

microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research’s (AACR) 101st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010. The posters will include data on


Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients

Demonstrate potential of miR-29c* to act as an independent prognostic factor for time to progression as well as survival after surgery Ability to forecast outcomes for malignant pleural mesothelioma (MPM) may enable clinicians to provide aggressive therapy to the most appropriate patients Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced


Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada

Rosetta Genomics, Ltd. (NASDQ:ROSG), the leading developer of microRNA-based molecular diagnostics, and Warnex Medical Laboratories, a division of Warnex Inc. (TSX:WNX), announced today they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests. Under the terms of the agreement, Warnex will market Rosetta Genomics’ miRview™ tests. Samples will be sent from


Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of a license and collaboration agreement under which Rosetta shall grant Prometheus U.S. rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview™ mets, miRview™ squamous and miRview™ meso. The terms


Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact 1-888-522-7971, or visit the company’s website "I am very excited to


Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

<p><strong>MicroRNAs as Potential Biomarkers — for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary (CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize Diagnosis and Treatment of Cancer</strong></p> <p><strong>Jersey City, NJ </strong> – Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of


NYU Medical Center Partners With Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers

Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that it has partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung, and Mesothelioma cancers. The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking,


Last update: April 01, 2019. 03:30:08 pm.